Disclosure of payments made to HCPs in Ireland
In recent years GSK has challenged the traditional commercial model of pharmaceutical companies with industry-leading improvements to how we do business. Our improvements aim to meet society’s growing expectation for organisations and individuals to act with transparency. This includes relationships between our industry and healthcare professionals (HCPs) or healthcare organisations (HCOs) so all of these interactions are conducted with integrity and transparency.
As members of the Irish Pharmaceutical Healthcare Association (IPHA), we fully support the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations.
As of 1 January 2016, GSK ended payments to external HCPs to speak about our prescription medicines or vaccines including to audiences who can prescribe or influence prescribing. Since January 2016 GSK has also stopped providing financial support directly to individual HCPs to attend medical congresses, and instead now provides funding to independent bodies which select HCPs to attend such congresses. These changes go further than the current industry codes and therefore others in the industry. We continue to work with HCPs for non-promotional activities such as clinical research.
Under the code, and by 30 June 2016, EFPIA member companies across Europe, including GSK, have pledged to disclose transfers of value made in 2015 to HCPs and HCOs in connection with prescription medicines on an individual-named basis (aggregate by exception only).
The disclosure includes, for example, sponsorship for travel and registration fees to attend medical congresses, HCP consultancy fees for speaker arrangements or for chairing meetings, and grants to HCOs. Transfers of value to HCPs and HCOs for activities related to research and development will be disclosed as an aggregate number. The disclosures we are making in June 2016 under the EFPIA code relate to 2015 before GSK ended these payments.
We believe these disclosures will help create a better understanding of how the pharmaceutical industry works with HCPs and HCOs. Given the measures GSK has put in place we seek to increase confidence in, and understanding of, how and why we work with healthcare professions for the sustainable improvement of healthcare and in the best interests of patients. More information on our approach to the EFPIA code, how are leading improvements to industry practices, and the importance of our partnerships with HCPs and HCOs can be found below, and is set out in greater detail here.
Our disclosures for Ireland may be viewed here